ARTICLE
17 November 2010

Pharmaceutical Inspectorate to Rule on Direct Drug Sales from Outside Poland

CC
CMS Cameron McKenna Nabarro Olswang

Contributor

CMS is a Future Facing firm with 79 offices in over 40 countries and more than 5,000 lawyers globally. Combining local market insight with a global perspective, CMS provides business-focused advice to help clients navigate change confidently. The firm's expertise and innovative approach anticipate challenges and develop solutions. CMS is committed to diversity, inclusivity, and corporate social responsibility, fostering a supportive culture. The firm addresses key client concerns like efficiency and regulatory challenges through services like Law-Now, offering real-time eAlerts, mobile access, an extensive legal archive, specialist zones, and global events.

The Chief Pharmaceutical Inspector is entitled to supervise all pharmaceutical trade in Poland, including trade by companies based outside Poland, according to the Voivodship Administrative Court in Warsaw.
Poland Food, Drugs, Healthcare, Life Sciences

The Chief Pharmaceutical Inspector is entitled to supervise all pharmaceutical trade in Poland, including trade by companies based outside Poland, according to the Voivodship Administrative Court in Warsaw.

The case was brought because the CPI had dismissed a request by the Polish Pharmaceutical Chamber to investigate the direct sale of drugs to Polish pharmacies by AstraZeneca UK Limited.

AstraZeneca sp. z o.o. was the first to introduce a direct drug distribution system in Poland, enabling it to sell its drugs directly to pharmacies. Its activities in Poland were based on cooperation with warehouses arranging the transportation of goods to buyers.

When the PPC raised concerns whether this was permitted by the rules governing small pharmacies' access to drugs under Polish pharmaceutical law, AstraZeneca revised its approach and used its UK company to make the sales.

When the PPC queried the lawfulness of the revised arrangement, the CPI declined to investigate on the grounds that it did not have jurisdiction over a trading company whose registered seat was outside Poland.
Now that this decision has been rejected by the Voivodship Administrative Court, the CPI will have to decide whether AstraZeneca's direct sales system complies with the law.

The outcome may result in restrictions being imposed on direct sales, which will affect not only companies based in Poland but also foreign companies taking advantage of the EC free movement of goods to sell their products in Poland. Any developments will be reported in Law-Now.

This article was written for Law-Now, CMS Cameron McKenna's free online information service. To register for Law-Now, please go to www.law-now.com/law-now/mondaq

Law-Now information is for general purposes and guidance only. The information and opinions expressed in all Law-Now articles are not necessarily comprehensive and do not purport to give professional or legal advice. All Law-Now information relates to circumstances prevailing at the date of its original publication and may not have been updated to reflect subsequent developments.

The original publication date for this article was 15/11/2010.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More